Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics

Simple item page
dc.contributor.authorAshrafizadeh, Milad
dc.contributor.authorAhmadi, Zahra
dc.contributor.authorMohamadi, Neda
dc.contributor.authorZarrabi, Ali
dc.contributor.authorAbasi, Sara
dc.contributor.authorDehghannoudeh, Gholamreza
dc.contributor.authorTamaddondoust, Rosette N.
dc.contributor.authorKhanbabaei, Hashem
dc.contributor.authorMohammadinejad, Reza
dc.contributor.authorThakur, Vijay Kumar
dc.date.accessioned2020-11-20T15:36:10Z
dc.date.available2020-11-20T15:36:10Z
dc.date.issued2019-12-20
dc.description.abstractPaclitaxel (PTX) and docetaxel (DTX) are key members of taxanes with high anti-tumor activity against various cancer cells. These chemotherapeutic agents suffer from a number of drawbacks and it seems that low solubility in water is the most important one. Although much effort has been made in improving the bioavailability of PTX and DTX, the low bioavailability and minimal accumulation at tumor sites are still the challenges faced in PTX and DTX therapy. As a consequence, bio-based nanoparticles (NPs) have attracted much attention due to unique properties. Among them, chitosan (CS) is of interest due to its great biocompatibility. CS is a positively charged polysaccharide with the capability of interaction with negatively charged biomolecules. Besides, it can be processed into the sheet, micro/nano-particles, scaffold, and is dissolvable in mildly acidic pH similar to the pH of the tumor microenvironment. Keeping in mind the different applications of CS in the preparation of nanocarriers for delivery of PTX and DTX, in the present review, we demonstrate that how CS functionalized-nanocarriers and CS modification can be beneficial in enhancing the bioavailability of PTX and DTX, targeted delivery at tumor site, image-guided delivery and co-delivery with other anti-tumor drugs or genes.en_UK
dc.identifier.citationAshrafizadeh M, Ahmadi Z, Mohamadi N, et al., (2020) Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics. International Journal of Biological Macromolecules, Volume 145, February 2020, pp. 282-300en_UK
dc.identifier.issn0141-8130
dc.identifier.urihttps://doi.org/10.1016/j.ijbiomac.2019.12.145
dc.identifier.urihttps://dspace.lib.cranfield.ac.uk/handle/1826/16024
dc.language.isoenen_UK
dc.publisherElsevieren_UK
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectChitosanen_UK
dc.subjectChemotherapyen_UK
dc.subjectNanoparticlesen_UK
dc.subjectPaclitaxelen_UK
dc.subjectDocetaxelen_UK
dc.subjectDeliveryen_UK
dc.titleChitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranosticsen_UK
dc.typeArticleen_UK

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
future_directions_in_cancer_theranostics-2020.pdf
Size:
1.19 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Staff publications (SATM)